LONDON, Dec. 19, 2016 /PRNewswire/ -- Immune system is an intricate network of various tissues, organs and cell that prevents the attack by infectious agents. It prevents the growth and development of pathogens in body that may cause disease development. Wide array of potential disease causing microorganism like bacteria, fungus and virus are identified and eliminated in the body. Immune system also has ability to identify self from foreign cells due to which transplant rejection is observed. It has capability to generate memory that helps in providing long-term memory. Dead and abnormal cell are removed from the body that may hinder the normal functioning of cellular processes. It could also be trained to identify and eliminate particular cells from the body by giving suitable cues. Investigators have utilized this property of immune system to treat diseases by modulating immune responses. Investigators have extended this modality for preventing cancer progression and proliferation by stimulating patients' immune system.
Cancer immunotherapies have evolved significantly and numerous products have been introduced in the market. Many cancer immunotherapies are being tested in clinical trials for identification of their pharmacological and commercialization potential. Novel cancer immunotherapies are at different stages of clinical trials which would be introduced in coming years in global market. They could be broadly divided in two classes: specific and non-specific cancer immunotherapy. Basis of this classification is their ability to identify specific antigen related to particular malignancy. Modality used for developing them may be different but all of them will involve the activation of immune system for elimination of cancer. In some cases, overlapping boundaries may be found which is quite possible because single cancer immunotherapy may have multiple effects.
Cancer immunotherapeutics segment seems to be quite dynamic as it has received highly developed products which are absent in other cancer therapeutic category. This category has large number of products belonging to different categories resulting in myriad choices for patients to choose suitable products according to their necessities. They have been able to create dominance in cancer market segment of pharmaceutical industry which is expected to be continued for several years. Some of the products belonging to cancer immunotherapy were introduced few decades ago, while others have received marketing approval in past few years.
Versatility of these cancer immunotherapies allow them to be administrated for different cancer indications due to which their market share is increasing. Different cancer immunotherapy products have different pharmacological profiles due to which some products shows more acceptance rates as compared to other cancer immunotherapies. However, they have superior pharmacological capabilities as compared to their conventional counterparts.
Cancer immunotherapies harbor targeted therapeutics for the treatment of some malignancies. They have been made to target few antigens putatively linked to the cancerous cells. As a result, they have been introduced for limited malignancies due which large unmet medical necessities are observed in this segment. This fact was recognized by pharmaceutical companies and they started to lay emphasis on identification of new biomarkers. Biomarker identification followed by their development is a complex process and requires lots of time. This issue was solved by using knowledge from bioinformatics and allied fields which has been able to save time, investments and precious resources. However, pharmacological and commercialization potential of cancer therapeutics based on novel biomarkers would be known by clinical data.
New modalities, biomarkers and underlying principles are expected to be introduced in global market in coming years. These changes are expected to be propelled by increased fundings and technological advancement in the field of cancer immunotherapeutics. This scenario shows that they are going to play an important role in the treatment of various malignancies. All these facts show that cancer immunotherapies are going to have an optimistic future.
Download the full report: https://www.reportbuyer.com/product/4397216/
About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com
For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com
SOURCE ReportBuyer
Share this article